Vancenase Aq

   
Google
 
Web NewDrugInformation.com

Vancenase Aq


Drug - Vancenase Aq
The trade name of the product as shown on the labeling.

Dosage - SPRAY, METERED; NASAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Beclomethasone Dipropionate Monohydrate
Multiple ingredients are in alphabetical order.

Strength - EQ 0.084MG DIPROP/SPRAY
The potency of the active ingredient(s), Beclomethasone Dipropionate Monohydrate. May repeat for multiple part products.

Applicant - SCHERING
The firm name holding legal responsibility for Vancenase Aq. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020469
The FDA assigned number to Vancenase Aq. Format is nnnnnn.

Product Number - 001
The FDA assigned number to identify Vancenase Aq. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jun 26, 1996
The date Vancenase Aq was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - No
The pioneer or innovator of Vancenase Aq. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - DISCN
The group or category of approved drugs Vancenase Aq is in. Format is RX, OTC, DISCN.

Applicant Full Name - Schering Corp
The full name of the firm holding legal responsibility for the new application of Vancenase Aq.

Vancenase Aq